耐甲氧西林金黄色葡萄球菌中赋予对利福霉素交叉耐药性的rpoB基因突变的分子特征分析
Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.
作者信息
Wichelhaus T A, Schäfer V, Brade V, Böddinghaus B
机构信息
Institute of Medical Microbiology, University Hospital of Frankfurt, Frankfurt am Main, Germany.
出版信息
Antimicrob Agents Chemother. 1999 Nov;43(11):2813-6. doi: 10.1128/AAC.43.11.2813.
Abstract
Mutations of the rpoB gene conferring resistance to rifampin were analyzed in 40 methicillin-resistant Staphylococcus aureus isolates obtained from six countries. Interestingly, the majority of clinical isolates showed multiple mutations within rpoB. The amino acid substitution 481His-->Asn was the most prevalent one, capable of conferring low-level resistance on its own. Cross-resistance to rifampin, rifabutin, and rifapentine was demonstrated for all mutants identified. The level of resistance to rifamycins correlated with both the mutation position and type of amino acid substitution.
摘要
对从六个国家获得的40株耐甲氧西林金黄色葡萄球菌分离株中赋予利福平抗性的rpoB基因突变进行了分析。有趣的是，大多数临床分离株在rpoB基因内显示出多个突变。氨基酸取代481His→Asn是最常见的一种，其自身就能赋予低水平抗性。对所有鉴定出的突变体均证明了对利福平、利福布汀和利福喷汀的交叉抗性。对利福霉素的抗性水平与突变位置和氨基酸取代类型均相关。
相似文献
1
Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌中赋予对利福霉素交叉耐药性的rpoB基因突变的分子特征分析
Antimicrob Agents Chemother. 1999 Nov;43(11):2813-6. doi: 10.1128/AAC.43.11.2813.
2
Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China.中国安徽某教学医院耐利福平金黄色葡萄球菌分离株的分子特征。
BMC Microbiol. 2012 Oct 22;12:240. doi: 10.1186/1471-2180-12-240.
3
Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.rpoB基因突变对利福平及KRM-1648抗金黄色葡萄球菌抗菌活性的差异影响。
J Antimicrob Chemother. 2001 Feb;47(2):153-6. doi: 10.1093/jac/47.2.153.
4
Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.韩国人工关节感染分离的葡萄球菌属菌株的利福霉素耐药性、rpoB 基因突变与临床结局
J Glob Antimicrob Resist. 2022 Mar;28:43-48. doi: 10.1016/j.jgar.2021.12.005. Epub 2021 Dec 14.
5
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.rpoB基因突变对结核分枝杆菌中利福霉素交叉耐药性产生的作用。
Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. doi: 10.1128/AAC.42.7.1853.
6
Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.利福霉素对野生型和利福平耐药结核分枝杆菌和大肠杆菌 RNA 聚合酶的体外抑制作用。
Tuberculosis (Edinb). 2011 Sep;91(5):361-9. doi: 10.1016/j.tube.2011.05.002. Epub 2011 Jun 24.
7
Emergence of rifampicin resistance in methicillin-resistant Staphylococcus aureus in tuberculosis wards.结核病房耐甲氧西林金黄色葡萄球菌中利福平耐药性的出现。
J Infect Chemother. 2006 Feb;12(1):47-50. doi: 10.1007/s10156-005-0417-8.
8
Biological cost of rifampin resistance from the perspective of Staphylococcus aureus.从金黄色葡萄球菌的角度看利福平耐药性的生物学代价。
Antimicrob Agents Chemother. 2002 Nov;46(11):3381-5. doi: 10.1128/AAC.46.11.3381-3385.2002.
9
In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.新型利福霉素对耐利福霉素金黄色葡萄球菌的体外活性
Antimicrob Agents Chemother. 2006 Mar;50(3):827-34. doi: 10.1128/AAC.50.3.827-834.2006.
10
Antimicrobial susceptibility of Staphylococcus aureus and characterization of methicillin-resistant Staphylococcus aureus isolated from bovine mastitis in Korea.韩国奶牛乳腺炎中产甲氧西林金黄色葡萄球菌的耐药性及耐药基因特征分析
Foodborne Pathog Dis. 2011 Feb;8(2):231-8. doi: 10.1089/fpd.2010.0661. Epub 2010 Oct 30.
引用本文的文献
1
Rifampin mediated decapsulation and enhanced bacterial clearance: a new mechanism of rifamycins.利福平介导的去包膜作用及增强细菌清除作用：利福霉素的一种新机制。
EBioMedicine. 2025 Jun 3;117:105787. doi: 10.1016/j.ebiom.2025.105787.
2
Identification of genetic mutations conferring tedizolid resistance in MRSA mutants.耐替加环素的耐甲氧西林金黄色葡萄球菌（MRSA）突变体中赋予替加环素抗性的基因突变鉴定
Eur J Clin Microbiol Infect Dis. 2025 May 13. doi: 10.1007/s10096-025-05157-x.
3
Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of .联合治疗在适应性实验室进化后可延缓抗菌药物耐药性。 （你提供的原文似乎不完整，“of”后面缺少具体内容）
Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0148324. doi: 10.1128/aac.01483-24. Epub 2025 Mar 14.
4
Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review.抗生素及抗生素耐药性的起源及其对药物研发的影响：一篇综述
Pharmaceuticals (Basel). 2023 Nov 15;16(11):1615. doi: 10.3390/ph16111615.
5
An Overview of Various Rifampicin Analogs against and their Drug Interactions.各种利福平类似物对抗 和它们的药物相互作用概述。
Med Chem. 2024;20(3):268-292. doi: 10.2174/0115734064260853230926080134.
6
Atopic dermatitis-derived strains: what makes them special in the interplay with the host.特应性皮炎相关菌株：它们在与宿主相互作用中有何特别之处。
Front Cell Infect Microbiol. 2023 Jun 14;13:1194254. doi: 10.3389/fcimb.2023.1194254. eCollection 2023.
7
Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis.肝硬化患者中肠细菌导致假体周围关节感染的发生率增加。
BMC Infect Dis. 2022 Apr 19;22(1):389. doi: 10.1186/s12879-022-07379-2.
8
Comparative Genomic Reveals Clonal Heterogeneity in Persistent Infection.比较基因组学揭示持续性感染中的克隆异质性。
Front Cell Infect Microbiol. 2022 Feb 21;12:817841. doi: 10.3389/fcimb.2022.817841. eCollection 2022.
9
Molecular Characterization of Rifampicin-Resistant Isolates from Retail Foods in China.中国零售食品中耐利福平分离株的分子特征分析
Antibiotics (Basel). 2021 Dec 4;10(12):1487. doi: 10.3390/antibiotics10121487.
10
Molecular Characteristics of Rifampin-Sensitive and -Resistant Isolates and Characteristics of Gene Mutations in Methicillin-Resistant .利福平敏感和耐药菌株的分子特征以及耐甲氧西林菌株中的基因突变特征
Infect Drug Resist. 2021 Nov 4;14:4591-4600. doi: 10.2147/IDR.S336200. eCollection 2021.
本文引用的文献
1
Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices?抗生素治疗耐甲氧西林金黄色葡萄球菌（MRSA）感染和消除 MRSA 携带。有哪些选择？
Int J Antimicrob Agents. 1997 Jun;9(1):1-19. doi: 10.1016/s0924-8579(97)00027-7.
2
Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.利福平、利福布汀和KRM-1648的抗分枝杆菌活性与结核分枝杆菌rpoB基因突变之间的关系。
J Antimicrob Chemother. 1998 Nov;42(5):621-8. doi: 10.1093/jac/42.5.621.
3
Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.金黄色葡萄球菌中赋予利福平抗性的rpoB基因突变的特征分析。
Antimicrob Agents Chemother. 1998 Oct;42(10):2590-4. doi: 10.1128/AAC.42.10.2590.
4
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.rpoB基因突变对结核分枝杆菌中利福霉素交叉耐药性产生的作用。
Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. doi: 10.1128/AAC.42.7.1853.
5
Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections.治疗耐甲氧西林金黄色葡萄球菌感染时万古霉素的替代药物。
J Antimicrob Chemother. 1998 Mar;41(3):325-8. doi: 10.1093/jac/41.3.325.
6
Clonal heterogeneity, distribution, and pathogenicity of methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌的克隆异质性、分布及致病性
Eur J Clin Microbiol Infect Dis. 1997 Dec;16(12):893-7. doi: 10.1007/BF01700555.
7
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.葡萄球菌中的耐甲氧西林特性：分子与生化基础及临床意义
Clin Microbiol Rev. 1997 Oct;10(4):781-91. doi: 10.1128/CMR.10.4.781.
8
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌：治疗现状与前景
Lancet. 1997 Jun 28;349(9069):1901-6. doi: 10.1016/s0140-6736(96)11192-2.
9
Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis.结核分枝杆菌中利福平耐药性及rpoB基因突变
FEMS Microbiol Lett. 1996 Oct 15;144(1):103-8. doi: 10.1111/j.1574-6968.1996.tb08515.x.
10
Antimicrobial activity of rifabutin.利福布汀的抗菌活性。
Clin Infect Dis. 1996 Apr;22 Suppl 1:S3-13; discussion S13-4. doi: 10.1093/clinids/22.supplement_1.s3.
Zotero 插件